{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000017","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.859853+00:00","generated_at":"2026-05-24T21:11:33.920950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M","bullets":["Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.","Net loss Q4 $22.8M vs net income $0.6M; FY2024 net loss $69.4M vs $51.9M.","Vafseo launch: shipments began Jan 9; >500 prescribers through Feb; Q1 revenue guidance $10-11M.","Cash $51.9M at Dec 31; post-year-end raised $18.4M ATM + $9.3M BlackRock; funded ≥2 years.","Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000017","json":"https://secwatch.observer/filing/0001517022-25-000017.json","markdown":"https://secwatch.observer/filing/0001517022-25-000017.md","text":"https://secwatch.observer/filing/0001517022-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/0001517022-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/akba-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:11:33.920950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}